Categories: HealthcareNews

Privia Health to Participate in the J.P. Morgan Healthcare Conference

ARLINGTON, Va., Jan. 03, 2023 (GLOBE NEWSWIRE) — Privia Health Group, Inc. (Nasdaq: PRVA) today announced that its management team plans to present and participate in a Q&A session at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 beginning at 6:00 pm ET / 3:00 pm PT.

The live webcast and replay of the event, as well as the accompanying slide presentation, will be available at ir.priviahealth.com/news-and-events/events-and-presentations.

About Privia Health

Privia Health™ is a technology-driven, national physician enablement company that collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual settings. Privia Health’s platform is led by top industry talent and exceptional physician leadership, and consists of scalable operations and end-to-end, cloud-based technology that reduces unnecessary healthcare costs, achieves better outcomes, and improves the health of patients and the well-being of providers. For more information, visit priviahealth.com.

Contact
Robert Borchert
SVP, Investor & Corporate Communications
IR@priviahealth.com
817.783.4841

Staff

Recent Posts

How Luciana Preger Is Helping Advance Gilead’s Work in Oncology

NORTHAMPTON, MA / ACCESSWIRE / June 12, 2024 / Gilead SciencesLuciana Preger credits being exposed…

3 hours ago

Clearstep Unveils Advanced Self-Service Booking for Specialist Care

New AI-driven technology integration marks a first in the U.S., enhancing patient access to specialized…

3 hours ago

Rutherrin(R) Increases Efficacy of Chemotherapy

TORONTO, ON / ACCESSWIRE / June 12, 2024 / Theralase® Technologies Inc. ("Theralase®" or the…

3 hours ago

Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Targeted protein degradation (TPD*) technologies have demonstrated the potential to produce novel treatment approaches Surrozen’s…

3 hours ago